Inozyme Pharma (INZY) Competitors $4.00 0.00 (0.00%) As of 07/1/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INZY vs. RCUS, DYN, SYRE, VERV, AVXL, MLYS, AVDL, NRIX, SANA, and LENZShould you be buying Inozyme Pharma stock or one of its competitors? The main competitors of Inozyme Pharma include Arcus Biosciences (RCUS), Dyne Therapeutics (DYN), Spyre Therapeutics (SYRE), Verve Therapeutics (VERV), Anavex Life Sciences (AVXL), Mineralys Therapeutics (MLYS), Avadel Pharmaceuticals (AVDL), Nurix Therapeutics (NRIX), Sana Biotechnology (SANA), and LENZ Therapeutics (LENZ). These companies are all part of the "pharmaceutical products" industry. Inozyme Pharma vs. Its Competitors Arcus Biosciences Dyne Therapeutics Spyre Therapeutics Verve Therapeutics Anavex Life Sciences Mineralys Therapeutics Avadel Pharmaceuticals Nurix Therapeutics Sana Biotechnology LENZ Therapeutics Arcus Biosciences (NYSE:RCUS) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment. Which has better earnings and valuation, RCUS or INZY? Inozyme Pharma has lower revenue, but higher earnings than Arcus Biosciences. Inozyme Pharma is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcus Biosciences$258M3.76-$283M-$4.19-2.18Inozyme PharmaN/AN/A-$102.02M-$1.69-2.37 Which has more volatility and risk, RCUS or INZY? Arcus Biosciences has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, Inozyme Pharma has a beta of 2.27, meaning that its stock price is 127% more volatile than the S&P 500. Do analysts prefer RCUS or INZY? Arcus Biosciences currently has a consensus target price of $21.29, suggesting a potential upside of 132.63%. Inozyme Pharma has a consensus target price of $11.75, suggesting a potential upside of 193.75%. Given Inozyme Pharma's higher probable upside, analysts clearly believe Inozyme Pharma is more favorable than Arcus Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcus Biosciences 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.89Inozyme Pharma 0 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.44 Is RCUS or INZY more profitable? Inozyme Pharma has a net margin of 0.00% compared to Arcus Biosciences' net margin of -258.94%. Arcus Biosciences' return on equity of -70.58% beat Inozyme Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Arcus Biosciences-258.94% -70.58% -32.97% Inozyme Pharma N/A -159.93%-82.48% Do institutionals and insiders hold more shares of RCUS or INZY? 92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 88.3% of Inozyme Pharma shares are owned by institutional investors. 9.6% of Arcus Biosciences shares are owned by insiders. Comparatively, 12.2% of Inozyme Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media refer more to RCUS or INZY? In the previous week, Arcus Biosciences had 3 more articles in the media than Inozyme Pharma. MarketBeat recorded 3 mentions for Arcus Biosciences and 0 mentions for Inozyme Pharma. Inozyme Pharma's average media sentiment score of 1.87 beat Arcus Biosciences' score of -0.14 indicating that Inozyme Pharma is being referred to more favorably in the news media. Company Overall Sentiment Arcus Biosciences Neutral Inozyme Pharma Very Positive SummaryArcus Biosciences beats Inozyme Pharma on 9 of the 16 factors compared between the two stocks. Get Inozyme Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INZY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INZY vs. The Competition Export to ExcelMetricInozyme PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$258.25M$2.96B$5.54B$9.41BDividend YieldN/A2.46%3.75%4.03%P/E Ratio-2.378.2821.0120.09Price / SalesN/A303.17433.8199.01Price / CashN/A42.5936.1658.27Price / Book4.447.678.125.65Net Income-$102.02M-$55.28M$3.25B$257.91M7 Day PerformanceN/A2.50%0.97%2.09%1 Month Performance0.50%11.70%7.36%11.13%1 Year Performance-24.81%4.89%31.31%18.40% Inozyme Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INZYInozyme Pharma3.5236 of 5 stars$4.00flat$11.75+193.8%N/A$258.25MN/A-2.3750Positive NewsRCUSArcus Biosciences2.3406 of 5 stars$9.66+3.5%$21.29+120.5%-39.0%$1.02B$258M-2.30500DYNDyne Therapeutics3.8968 of 5 stars$8.91+3.1%$41.13+361.6%-77.3%$1.01BN/A-2.48100Analyst ForecastInsider TradeSYRESpyre Therapeutics1.9298 of 5 stars$16.41+4.6%$53.40+225.4%-46.2%$989.20M$890K-4.3573VERVVerve Therapeutics2.8995 of 5 stars$11.03flat$14.57+32.1%+45.8%$983.25M$59.61M-5.23110AVXLAnavex Life Sciences3.924 of 5 stars$11.48+3.3%$44.00+283.3%+86.8%$980.05MN/A-20.8740MLYSMineralys Therapeutics2.2236 of 5 stars$15.02+3.7%$32.25+114.7%+3.2%$979.00MN/A-4.0328Insider TradeAVDLAvadel Pharmaceuticals1.8367 of 5 stars$10.04+4.5%$18.17+80.9%-33.4%$971.26M$194.45M-37.1970Analyst ForecastNRIXNurix Therapeutics2.4806 of 5 stars$12.69+2.0%$29.47+132.2%-44.5%$970.15M$54.55M-4.86300Analyst ForecastAnalyst RevisionSANASana Biotechnology3.2939 of 5 stars$4.22+1.0%$9.17+117.2%-30.3%$951.51MN/A-4.80380Positive NewsGap UpLENZLENZ Therapeutics1.3396 of 5 stars$33.73-2.8%$46.60+38.2%+58.5%$949.37MN/A-19.06110 Related Companies and Tools Related Companies Arcus Biosciences Alternatives Dyne Therapeutics Alternatives Spyre Therapeutics Alternatives Verve Therapeutics Alternatives Anavex Life Sciences Alternatives Mineralys Therapeutics Alternatives Avadel Pharmaceuticals Alternatives Nurix Therapeutics Alternatives Sana Biotechnology Alternatives LENZ Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INZY) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inozyme Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inozyme Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
